针药结合治疗脑梗死的临床观察
|
摘要
目的：系统观察针药结合治疗脑梗死在不同时期的临床疗效。
方法：将符合纳入标准的患者按入院时间分为超早期、急性期和恢复期分别进行观察。
超早期：将符合纳入标准的18例患者归类为针药组8例和单纯溶栓组10例。在超早期单纯溶栓组仅以溶栓药物治疗,针药组在溶栓之后予以针刺治疗1次。2组在急性期均予以依达拉奉、丹参酮及奥扎格雷钠治疗。以14天为一个疗程,以神经功能缺损评分和FMA评分为评价指标,在治疗1天后及14天后进行临床疗效评价。
急性期：将符合纳入标准的30例患者随机分为针药组14例和药物组16例,针药组予以依达拉奉、丹参酮及奥扎格雷钠治疗及针刺治疗,药物组仅予以上述西药治疗,以14天为一个疗程,以神经功能缺损评分和FMA评分为评价指标,在疗程结束后进行临床疗效评价。
恢复期：将符合纳入标准的34例患者随机分为针药组12例,药物组12例,针刺组10例,针药组予以针剌疗法及乙酰谷酰胺、奥扎格雷钠、丹参酮治疗,药物组仅予以上述西药治疗,针刺组仅予以针刺治疗,以14天为1个疗程。以神经功能缺损评分和B I指数为评价指标,在疗程结束后进行临床疗效评价。
结果：
超早期：治疗14天后,2组均取得较好的临床疗效,针药组有效率为87.5%,单纯溶栓组有效率为90%,针药组与单纯溶栓组相比无统计学差异,P>0.05；治疗1天及14天后两组的神经功能缺损评分及肢体运动功能评分均无明显差异,P>0.05。
急性期：治疗14天后,2组均取得较好的临床疗效,针药组有效率为100%,药物组有效率为87.5%,2组相比无统计学差异,P>0.05；两组的神经功能缺损评分及肢体运动功能评分均有统计学差异,P<0.05。
恢复期：治疗14天后,3组均取得一定的临床疗效,针药组有效率为83.3%,针刺组为80%,药物组为41.3%。3组神经功能缺损评分、Barthel指数评分及临床疗效显示针药组与针刺组均优于药物组,均P<0.05,而针刺组与针药组比较无统计学差异,P>0.05。
结论：对于脑梗死患者的治疗,①超早期(6h内)溶栓药物发挥了主要作用,针药结合优势不明显；②急性期(6h后至14天内)神经保护剂和针药结合均具有显著疗效,针药结合并未取得疗效优势,但在神经功能改善和运动功能康复方面仍有明显优势；③恢复期(14天至60天内)针灸发挥了主要的作用,针药结合优势不明显。
Objective:To Systematic observation Acupuncture treatment of cerebral infarction in the clinical efficacy of different periods.
Methods:The patients met the inclusion criteria were divided into two super-early admission, acute and convalescent phase were observed.
Ultra-early:to meet the inclusion criteria of the 18 patients classified as acupun cture group and 8 cases of 10 patients with thrombolysis alone. Only thrombolytic therapy thrombolytic group, acupuncture group to be treated with acupuncture after thrombolytic 1.2 Groups will be in the acute phase of edaravone, Tan, and ozagrel treatment.14-day cycle, With neurological deficit score and FMA score assessed 1 day after treatment and 14 days after the change, respectively the treatment.
Acute phase:the 30 cases meeting the inclusion criteria were randomly divided into acupuncture group and drug group in 14 cases,16 cases to be edaravone treated group, Tan and Ozagrel therapy and acupuncture therapy group to be the only Western treatment to 14 days for a treatment to neurological deficit score and FMA score for the evaluation of indicators, after the end of treatment clinical evaluation.
Recovery:The 34 patients met the inclusion criteria were randomly divided into acupuncture group 12 cases,12 cases of simple drug group,10 cases of simple acupuncture group, Acupuncture and acetyl group to glutamine, ozagrel, Tan, western medicine to be simple drug group only treatment, only to be simple acupuncture acupuncture treatment to 14 days to a course of treatment. With neurological deficit score and the BI index for the evaluation, the clinical effect after the end of treatment evaluation.
Result:Ultra-early:After 14 days of treatment,2 groups were simply made good clinical efficacy, acupuncture group was 87.5% effective, simple and effective rate of 90% of the thrombolytic group, acupuncture group compared with thrombolysis alone no significant difference, P> 0.05; treatment of 1 day and 2 weeks after the two groups of neurological deficit score and limb motor function score were not significantly different, P> 0.05.
Acute phase:After 14 days of treatment,2 groups were achieved better clinical efficacy, acupuncture group was 100% effective, the effective rate of 87.5% drug group, compared with no significant difference between 2 groups P>0.05; two groups of nerve function deficit score and limb motor function score were signify cantly different,P<0.05.
Recovery period:After 2 weeks of treatment, three groups have achieved a certain degree of clinical efficacy, acupuncture group was 83.3%, acupuncture group, 80%, drug group was 41.3%. Group 3 neurological deficit score Barthel Index score and the clinical efficacy have shown that needle acupuncture group was better than drugs and drug group, both P<0.05, while The acupuncture group and the acupuncture group showed no significant difference, P> 0.05.
Conclusion:For the treatment of patients with cerebral infarction,①super early (6h period) played a major role in thrombolytic drugs, acupuncture combined with obvious advantages;②acute phase (6 hours to 14 days), and neuroprotective agents all have Acupuncture significant effect, Acupuncture efficacy advantage was not achieved, but neurological improvement and rehabilitation of motor function is still obvious advantage③In the recovery period (14 days to 60 days), played a major role in acupuncture, acupuncture combined with obvious advantages.
方法：将符合纳入标准的患者按入院时间分为超早期、急性期和恢复期分别进行观察。
超早期：将符合纳入标准的18例患者归类为针药组8例和单纯溶栓组10例。在超早期单纯溶栓组仅以溶栓药物治疗,针药组在溶栓之后予以针刺治疗1次。2组在急性期均予以依达拉奉、丹参酮及奥扎格雷钠治疗。以14天为一个疗程,以神经功能缺损评分和FMA评分为评价指标,在治疗1天后及14天后进行临床疗效评价。
急性期：将符合纳入标准的30例患者随机分为针药组14例和药物组16例,针药组予以依达拉奉、丹参酮及奥扎格雷钠治疗及针刺治疗,药物组仅予以上述西药治疗,以14天为一个疗程,以神经功能缺损评分和FMA评分为评价指标,在疗程结束后进行临床疗效评价。
恢复期：将符合纳入标准的34例患者随机分为针药组12例,药物组12例,针刺组10例,针药组予以针剌疗法及乙酰谷酰胺、奥扎格雷钠、丹参酮治疗,药物组仅予以上述西药治疗,针刺组仅予以针刺治疗,以14天为1个疗程。以神经功能缺损评分和B I指数为评价指标,在疗程结束后进行临床疗效评价。
结果：
超早期：治疗14天后,2组均取得较好的临床疗效,针药组有效率为87.5%,单纯溶栓组有效率为90%,针药组与单纯溶栓组相比无统计学差异,P>0.05；治疗1天及14天后两组的神经功能缺损评分及肢体运动功能评分均无明显差异,P>0.05。
急性期：治疗14天后,2组均取得较好的临床疗效,针药组有效率为100%,药物组有效率为87.5%,2组相比无统计学差异,P>0.05；两组的神经功能缺损评分及肢体运动功能评分均有统计学差异,P<0.05。
恢复期：治疗14天后,3组均取得一定的临床疗效,针药组有效率为83.3%,针刺组为80%,药物组为41.3%。3组神经功能缺损评分、Barthel指数评分及临床疗效显示针药组与针刺组均优于药物组,均P<0.05,而针刺组与针药组比较无统计学差异,P>0.05。
结论：对于脑梗死患者的治疗,①超早期(6h内)溶栓药物发挥了主要作用,针药结合优势不明显；②急性期(6h后至14天内)神经保护剂和针药结合均具有显著疗效,针药结合并未取得疗效优势,但在神经功能改善和运动功能康复方面仍有明显优势；③恢复期(14天至60天内)针灸发挥了主要的作用,针药结合优势不明显。
Objective:To Systematic observation Acupuncture treatment of cerebral infarction in the clinical efficacy of different periods.
Methods:The patients met the inclusion criteria were divided into two super-early admission, acute and convalescent phase were observed.
Ultra-early:to meet the inclusion criteria of the 18 patients classified as acupun cture group and 8 cases of 10 patients with thrombolysis alone. Only thrombolytic therapy thrombolytic group, acupuncture group to be treated with acupuncture after thrombolytic 1.2 Groups will be in the acute phase of edaravone, Tan, and ozagrel treatment.14-day cycle, With neurological deficit score and FMA score assessed 1 day after treatment and 14 days after the change, respectively the treatment.
Acute phase:the 30 cases meeting the inclusion criteria were randomly divided into acupuncture group and drug group in 14 cases,16 cases to be edaravone treated group, Tan and Ozagrel therapy and acupuncture therapy group to be the only Western treatment to 14 days for a treatment to neurological deficit score and FMA score for the evaluation of indicators, after the end of treatment clinical evaluation.
Recovery:The 34 patients met the inclusion criteria were randomly divided into acupuncture group 12 cases,12 cases of simple drug group,10 cases of simple acupuncture group, Acupuncture and acetyl group to glutamine, ozagrel, Tan, western medicine to be simple drug group only treatment, only to be simple acupuncture acupuncture treatment to 14 days to a course of treatment. With neurological deficit score and the BI index for the evaluation, the clinical effect after the end of treatment evaluation.
Result:Ultra-early:After 14 days of treatment,2 groups were simply made good clinical efficacy, acupuncture group was 87.5% effective, simple and effective rate of 90% of the thrombolytic group, acupuncture group compared with thrombolysis alone no significant difference, P> 0.05; treatment of 1 day and 2 weeks after the two groups of neurological deficit score and limb motor function score were not significantly different, P> 0.05.
Acute phase:After 14 days of treatment,2 groups were achieved better clinical efficacy, acupuncture group was 100% effective, the effective rate of 87.5% drug group, compared with no significant difference between 2 groups P>0.05; two groups of nerve function deficit score and limb motor function score were signify cantly different,P<0.05.
Recovery period:After 2 weeks of treatment, three groups have achieved a certain degree of clinical efficacy, acupuncture group was 83.3%, acupuncture group, 80%, drug group was 41.3%. Group 3 neurological deficit score Barthel Index score and the clinical efficacy have shown that needle acupuncture group was better than drugs and drug group, both P<0.05, while The acupuncture group and the acupuncture group showed no significant difference, P> 0.05.
Conclusion:For the treatment of patients with cerebral infarction,①super early (6h period) played a major role in thrombolytic drugs, acupuncture combined with obvious advantages;②acute phase (6 hours to 14 days), and neuroprotective agents all have Acupuncture significant effect, Acupuncture efficacy advantage was not achieved, but neurological improvement and rehabilitation of motor function is still obvious advantage③In the recovery period (14 days to 60 days), played a major role in acupuncture, acupuncture combined with obvious advantages.
引文
[1]杨期东.神经病学[M].北京：人民卫生出版社,2002：118
[2]王维治.神经病学.第4版[M].北京：人民卫生出版社,2002：130-14.
[3]范刚启,蔡辉,赵凌杰等.对目前针灸治疗中风病研究的几点建议[J].中国针灸2004,4(6)：434-436
[4]徐斌,陆金平,孙建华等针药结合对缺血性脑血管病患者血浆神经肽的影响[J].中国临床康复,19(7)：2646-2647
[5]Ahagon A Ishikawa M Handa H Histochemical changes of brain dopamine in an Acute stage of cerebral ischemia in gerbils.Stroke.1980, 11(6):622-628
[6]Block F Peters M Nolden-Koch M ExPression of IL-6 in the ischemic pneumbra Neurosci Lett,1999,262:117
[7]Yang GY, Schielke GP,Gong C,Expression of Tumor necrosis factor-alpha and intercellular adhesion molecule-1 after focal cerebral ischemia in interlukin-lbeta converting enzyme deficient mice.J Cereb Blood Flow Metab,1999,19(10):1109-1117
[8]王竞,杜俊蓉.缺血性脑损伤机制的研究进展[J].国际药学研究杂志,2008,35(4)：302-304.
[9]Hunter AJ.Calcium channel antagonists:their role in neuroProtection.In:Agreen AR, Cross AJ.eds. Neuroteetive Agents and cerebral Isehemia.San Diego;Academic Press.1997,95-108.
[10]Ereeeeinska M,Silver IA.Loss of neuronal caleium homeostasis in isghemia.In:Weleh KMA, Reis DJ, Caplan LR, eds.Primer on Gerebrovaseular Diseases.NewYork:ACademic press Limited,1997,178-183.
[11]Small DL, Morley P, Buehan of isehemic cerebral cell death.Prog CardiovaseDis,1999, 42(3):85-207.
[12]Mies QKohno K,Hossman KA,MK-801,a glutmate antagonist,lowers flow threshold for inhibition of protein synthesis after middle cerebral artery occlusion of rat.Neurosci Lett,1993,155(1):65-68.
[13]Rother J,de-Crespingny AJ,D Arceuil H et al.Stroke,1996,27:980
[14]Kohon K,Hoehn-Berlage M, Mies QRelationship between diffusion-weighted MR images,cewebral biood flow,and energy state in experimental brain infarction.Magn Reson Imaging,1995,13(1):73-80.
[15]Fatar M,Stroick M,Griebe M,.et al.Matrixmetallo proteinases in cerebrovascular diseases. Cerebrovasc Dis,2005,20:141-151.
[16]Cunningham LA,Wetzel M,Rosenberg GA.Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia,2005,50:329-339.
[17]Zoppo GJ,Milner R,Mabuchi T,et al.Microglial activation and matrix protease generation during focal cerebral ischemia.Stroke,2007,38:646-651.
[18]Lewen A,Mqtz P,Chan PH.Free radial Pathways in CNS injury.J neurotrauma.2000,17(10):871-890.
[19]Doyle KP, Simon RP, Stenztl-PeoreMP. Mechanisms of ischemic brain damage [J].Neuropharmacology,2008, do:i 10.1016/j neuropharm.2008.01.005
[20]Duan W,Gui L,Zhou Z,et al.Adenosine A(2A)receptor deficiencyexacerbates white matter lesions and cognitive deficits induced bychronic cerebral hypoperfusion in mice[J].Neurol Sci,2009,285(1):39-45.
[21]Stanimirovic D,Satoh K.Inflammatory mediations of cerebral endothelium:amole in ischemic brain inflammtion.Brain Pathol,2000,10(1):113-126.
[22]Vilan N,Castillo J,DavolosA,et al.Proinflamatory cytokines and early neurological worsening in ischemic stroke[J].Stroke,2000,31(10):2325-2329.
[23]Feuerstein GZ, Liu T, Barone FC. Cytokines,inflammation, and brain injury:role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev,1994,6(4):341-360.
[24]Ritter LS,Orozco JA,Coull BM,et al.Leukocyte accumulation and hemodynamic changes in the cerebral microcriculation during early reperfusion after stroke,2000,31(5):1153-1161.
[25]Del Zoppo GJ,Schmid-Schonbein GW,Mori E,et al.Polymorphonucl-ear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons.Stroke,1991,22:1276-1283.
[26]Kochanek P,Hallenbeck JM.Polymorphonuclear Leukocytes and Monmcytes/Macrophages in the Pathogenesis of Cerebral Ischemia and Stroke.Stroke,1992,23(9):1367-1375.
[27]滕厚军,赵瑛.慢性脑缺血神经胶质细胞损伤与血管性痴呆的研究进展[J].中国脑血管病杂志,2008,5(10)：473-476.
[28]Streit WJ,Walter SA,Pennell NA.Reactive microgliosis [J]. ProgNeurobiol,1999,57(6):563-581.
[29]Siesjo BK:Cell damagr in the brain:A speculative synthesis.J CerebBloodFlowMetab,1981; 1:155-85.
[30]Portera-Cailliau C,Price DL,Martin LJ,Excitotoxic neuronal death in the immature brain is an apoptosis-necrosis morphological continuum.J Comp Neurol,1997,378(1):70-87.
[31]Koh JY, Suh SW, Gwag BJ,et al. The role of zinc inselective neuronal death following transient global ischemia. Science,1996,272:1013-1016.
[32]Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol,1996,6:667-672.
[33]丁宏岩,董强.肝素体外诱导低密度脂蛋白—载脂蛋白a—纤维蛋白原沉淀系统在脑梗死中的临床应用[J].国外医学脑血管疾病分册,2002, (10)5：370-373.
[33]余巧燕,孙晋民.溶栓药物的研究进展[J].医学理论与实践,2009,22(1)：30-33
[34]Del Zoppo GJ,Saver JL,Jauch EC,et al;Amercian Heart Association Stroke Council.Expansion of the window for treatment of actue ischemic stroke with intravenous tissue plasminogen activator:a science advisory from the American heart Association.Stoke,2009,40:2945-2948
[35]朱丽君.急性脑梗死的药物治疗[J].急性脑梗死的药物治疗,2008,29(1)：48-51.
[36]刘庆新,张苏明.急性脑出血继发缺血半暗带的研究进展[J].国外医学：脑血管疾病分册,2002,10(3)：191-194.
[37]匡培根.神经系统疾病药物治疗学[M].北京：人民卫生出版社,2002：241-250
[38]冯留信.神经保护治疗的现状及进展[J].中国现代医生.2008,46,(6)：72-73
[39]章祥.脑卒中诊断治疗学[M].北京：人民军医出版社,2002：102-103
[40]Yuki S,Kogure K.The changes of LCGU and rCBF in the MCA Oclusion recirculation model in rats and the ameliorating efect of MCI-186,a novel free radical scavenger.Mol Chem Neuropathol,1997,32(1-3):123-128.
[41]Takahashi QSakurai M,Abe K,et al.MCI-186 prevents spinal cord damage and affects enzyme levels of nitric oxide synthase and Cu/Zn superoxide dismutase after transient ischemia in rabbits[J].J Thorac Cardiovasc Surg,2003,126(5):1461-1466.
[42]Gu Z,Kaul M,Yan B,et al.Snitrosylation of matrix metalloproteinases:signaling pathway to neuronal cell death. Science,2002,297 (5584):1186-1190.
[43]Higashi Y.Edaravone for the treatment of acute cerebral infarction:role ofendothelium derived nitric oxide and oxidative stress[J].Expert Opin Pharmacother,2009,10(2):323-331.
[44]Xiao B,Bi FF,Hu YQ,et al.Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats[J].Neurotox Res,2007,12(3):155-162.
[45]朱东铭,罗成宏.依达拉奉治疗高血压脑出血的临床疗效观察[J].国际医药卫生导报,2006,12(31)：88-89
[46]Visse R,Nagase H.Matrix metalloproteinases and tissue inhibitors of metalloproteinases:structure,function,and biochemistry. CircRes,2003,92(8):827-839.
[47]胡海涛,吴继敏,王爽,等.依达拉奉对大鼠局灶性脑缺血的保护作用[J].中国药学杂志, 2005,40(19)：1463.
[48]ToyodaK, FujiiK, KamouchiM, et a.l Free radical scavenger,edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci,2004,221:11-17.
[49]邓树荣.脑缺血亚低温脑保护研究的进展与临床应用[J].医学文选,2003,23(4)：557-559
[50]丁宏岩,董强.肝素体外诱导低密度脂蛋白—载脂蛋白a—纤维蛋白原沉淀系统在脑梗死中的临床应用[J].国外医学脑血管疾病分册,2002, (10)5：370-373.
[51]Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemicstroke. Cochrane Database Syst Rev,2004, (3):24.
[52]Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med,1995,333:1588-1593.
[53]The Publications Committee for the Trial of ORG10172in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid,ORG10172(danaparoid), and outcome after acute ischemic stroke:a randomized controlled trial. JAMA,1998,279:1265-1272.
[54]杨友松,高国勋血液稀释疗法及其临床应用系统评价[J].实用医院临床杂志,2008,3,(5)：26-28
[55]FRIEDRICH G, IUCA R, HEINRICHM, eta.l local intra-arterial thrombolysis in acute ischemic stroke[J]. Stroke,1998,29:1894-1900.
[56]TOSHIHIRO M D, SABURO M D, ICHIRO M D,et al.Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries[J]. Stroke,1998,29:2568-2574.
[57]国家中医药管理局脑病急症协作组.中风病诊断与疗效评定标准(试行)[J].北京中医药大学学报,1996,19(1)：55-56
[58]谭红刚,辨证治疗脑梗死120例[J].光明中医,2006,21(5)：67-68
[59]缪钟丽.中风证治十法[J].山东中医志,1995,2(14)：58-59
[60]蒋红玉.缺血性中风108例临床观察[J].中医杂志,1996(2)：96-97
[61]王建华,王永炎.出血性中风＆缺血性中风急性期证候演变规律的研究[J].中国中医急症,2001,10(4)：215-217
[62]沈思钰,傅晓东,钱善风.中医药对缺血性中风神经保护作用的机理探讨及评价[J].中国中医急症,2004,13(12)：838-839
[63]黄选华.辨证通腑治疗中风急性期96例疗效观察[J].广西中医学院学报,2001,18(1)：47
[64]屈营,董雪.中风辨证治疗恢复期中风106例[J].辽宁中医学院学报,2002,4(4)：300
[65]张树泉.调气法在急性脑梗死溶栓治疗中的应用[J].山东中医杂志,2005,24(5)：265-266
[66]裘昌林.中风病研究概况[J].浙江中西医结合杂志,2000,10(12)：705-707
[67]王妍,李成.清开灵治疗脑卒中急性期34例[J].天津中医,2000,17(3)：15—17
[68]刘方,白文.醒脑静注射液治疗急性脑血管病35例临床研究[J].中西医结合心脑血管病杂志,2004,2(9)：511-513
[69]于锋,金亦涛,綦春玉等.脉络宁注射液药理学研究进展[J].中国新药杂志,2002,11(12)：920-924
[70]肖勤选,金香兰,蒋红信等.脉络宁治疗急性期脑梗塞398例临床疗效观察[J].辽宁医学杂志,2001,15(2)：97-98.
[71]陆寿康.头针治疗中风偏瘫及其疗效的评估[J].中医杂志,1991,(10)：49.
[72]马松涛.头针治疗中风偏瘫的临床观察[J].河北中医,1993,15(1)：28.
[73]于致顺.头针刺激区与头部腧穴关系[J].中医药学报,1987,1(1)：7.
[74]石宪,张志芳,李晓燕,等.头部“菱形区”,治疗中风偏瘫的临床研究[J].针灸学报,1991,7(3)：35.
[75]许佳年,贾怡蓓,韩天雄,武雪宇,陈佳红,庄海春.针药结合对脑梗塞患者血脂和血液流变学的影响[J].辽宁中医杂志,2006,33(12)：1528-1529.
[76]李熳,穆腊梅.头针疗法治疗中风进展[J].中国针灸,1993,11(3)：87.
[77]沈特立,周冬梅,王兴.头针治疗急性脑梗塞70例临床研究[J].针灸临床杂志,2000,16(2)：31-33
[78]张丹莉.针刺阳明经榆穴对脑卒中患者运动功能的影响[J].中国临床康复.2005,9(13)：148.
[79]王友仁,徐止帆.针药综合治疗中风偏瘫144例[J].江苏中医.1995,(1)：39.
[80]石学敏.针刺治疗中风病的临床研究[J].上海针灸杂志,1992,(4)：4.
[81]申鹏飞,石学敏.针刺对急性期超早期脑梗死患者脑氧代谢的影响[J].光明中医,2009,24(2)：303-305.
[82]许能贵,马勤耘,许冠蒸等.电针对局灶性脑缺血大鼠脑血流量、脑含水量,SOD,MDA的影响[J].针刺研究,1998,23(3)：175.
[83]许能贵,马勤耘,侯思伟.电针对局灶性脑缺血大鼠兴奋性氨基酸含量的影响[J].中国针灸,1999,19(7)：431-432.
[84]许能贵,马勤耘,朱舜丽等.电针对局灶性脑缺血大鼠中枢单胺类神经递质的影响[J].中国中医基础医学杂志,1999,5(12)：56-57.
[85]郑谅,江钢辉,李艳慧.调和阴阳法治疗中风偏瘫的临床研究[J].针刺研究,1999,24(4)：249-250.
[86]常亮,侯本赤.针刺井穴治疗脑卒中下肢弛缓性瘫痪22例[J].辽宁中医学院学报,2006,(3)：102.
[87]殷克敬,杜元灏,王瑞辉.针刺治疗中风急性期机理研究[J].针灸临床杂志,1997,8：16-19..
[88]范刚启.针灸治疗中风病[M].上海：第一军医大学出版社,2001：120-123.
[89]雷龙鸣,吴林,胡跃强.不同针刺方案对脑梗死偏瘫患者康复及病灶侧大脑中动脉平均血流速度的影响[J].中国针灸,2009,29(7)：517-520.
[90]张晓霞,冯毅.火针治疗缺血性中风的临床观察[J].北京中医,2001,5,54-55.
[91]姜华,王满侠,郭健等.子午流注纳甲法治疗急性缺血性脑血管病及对IL-6水平的影响[J].甘肃中医学院学报,2003,20(1)：45-47.
[92]高先凤,川芎嗪穴位注射对脑梗死肢体功能恢复的疗效观察[J].中医药临床杂志,2008,20(6)：583-584.
[93]石奕丽刺络拔罐法治疗假性球麻痹46例临床观察[J].河北中医,1997,19(2)：43.
[94]郭义,周智良,周国平,等1中风初起的急救措施——手十二井穴刺络放血法的临床与实验研究[J].上海针灸杂志,1997,16(2)：11.
[95]韩宝杰,刺络疗法对中风病患者血液.变学影响的临床观察[J].天津中医,2001,18(1)：28-29.
[96]解庆凡,田胜利等.大全息针法治疗中风偏瘫230例临床观察[J].北京中医药大学学报,2005,23(3)：74
[97]曹岱,赵辉等.马丹阳天星十二穴担截法治疗缺血性中风临床研究[J].中国针灸,2002,22(9)：591
[98]徐斌,陆金平,孙建华等.针药结合对缺血性脑血管病患者血浆神经肽的影响[J].中国临床康复,19(7)：2646-2647
[99]许佳年,贾怡蓓,韩天雄等.针药结合对脑梗塞患者血脂和血液流变学的影响[J].辽宁中医杂志,2006,33(12)：1528-1529.
[100]陈莉秋.针药结合治疗脑梗死32例疗效观察[J].河北中医,2008,30(1)：67-68.
[101]李宗桥,韩永,陈会君.针药结合对急性脑梗死患者神经功能恢复的影响[J].针灸临床杂志,2006,22(10)：25-26.
[102]高建平,邱霞,廉世松.早期补肾醒脑针法干预缺血性中风患者神经功能缺损的临床观察[J].中华中医药杂志,2008,23(4)：367-368.
[103]金智秀,图娅,洪银珠等.头针、体针和针药结合治疗对全脑缺血大鼠钙调素活性即 刻影响的比较研究[J].针刺研究,2004,29(14)：18-19
[104]马惠芳,郭长青,邬继红等.针刺“水沟”穴与针药结合对实验性全脑缺血大鼠脑组织钙调素活性影响的实验研究[J].北京中医药大学学报,2003,26(1)：84-85
[105]陶陶,徐坚,董佑忠等.电针及天麻对大鼠脑缺血再灌注后神经细胞凋亡及相关蛋白Bcl-2、 Bax表达的影响[J].中国针灸,2004,24(9)：645-648
[106]成泽东,陈以国,王树东.针药结合对脑缺血再灌注大鼠血清SOD、 MDA及海马组织超微结构的影响[J].中医研究,2008,21(10)：9-11
[107]严文广,谢雪姣,黄政德等.针药结合干预大鼠局灶性脑缺血组织ATP酶活性及能量代谢的研究[J].湖南中医药大学学报,2007,27(3)：59-62
[108]全国第四界脑血管疾病会议.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29,(6)：381.
[109]中华医学会全国第四次脑血管病学术会议.脑卒中患者神经功能缺损程度评分标准[S].中华神经科杂志,1996,29(6)：381-383
[110]杨志新,石学敏,醒脑开窍针刺法治疗中风疗效与安全性的系统评价[J].中国针灸,2007,27(8)：601-607.
[111]王茂斌.脑卒中偏瘫患者肢体运动功能的头针评测方法[J].中国头针医学杂志,1992,7(2)：81.
[112]Keith RA, Granger CV, Hamilton BB, et al. The functional independence measure:a new tool for rehabilitation.In:Eisenberg M, Grzesia R.eds. Advances in clinical rehabilitation [M]. NewYork:SpringeVerlag,1987:6-18.
[113]Holbrook M, Skilbeck CF. An activities index for use with stroke patients [J]. Age Ageing,1983,12:166-170
[114]周维金,孙启良.瘫痪康复评定手册[M].北京：人民卫生出版社,2006：12-20.
[115]王志义.中药、针刺、针药并举对脑卒中偏瘫康复的疗效对比分析[J].现代康复,2001,5(6)：130
[116]高希言等.针药结合研究的探讨[J].中医杂志,1999,40(9)：562-563
[2]王维治.神经病学.第4版[M].北京：人民卫生出版社,2002：130-14.
[3]范刚启,蔡辉,赵凌杰等.对目前针灸治疗中风病研究的几点建议[J].中国针灸2004,4(6)：434-436
[4]徐斌,陆金平,孙建华等针药结合对缺血性脑血管病患者血浆神经肽的影响[J].中国临床康复,19(7)：2646-2647
[5]Ahagon A Ishikawa M Handa H Histochemical changes of brain dopamine in an Acute stage of cerebral ischemia in gerbils.Stroke.1980, 11(6):622-628
[6]Block F Peters M Nolden-Koch M ExPression of IL-6 in the ischemic pneumbra Neurosci Lett,1999,262:117
[7]Yang GY, Schielke GP,Gong C,Expression of Tumor necrosis factor-alpha and intercellular adhesion molecule-1 after focal cerebral ischemia in interlukin-lbeta converting enzyme deficient mice.J Cereb Blood Flow Metab,1999,19(10):1109-1117
[8]王竞,杜俊蓉.缺血性脑损伤机制的研究进展[J].国际药学研究杂志,2008,35(4)：302-304.
[9]Hunter AJ.Calcium channel antagonists:their role in neuroProtection.In:Agreen AR, Cross AJ.eds. Neuroteetive Agents and cerebral Isehemia.San Diego;Academic Press.1997,95-108.
[10]Ereeeeinska M,Silver IA.Loss of neuronal caleium homeostasis in isghemia.In:Weleh KMA, Reis DJ, Caplan LR, eds.Primer on Gerebrovaseular Diseases.NewYork:ACademic press Limited,1997,178-183.
[11]Small DL, Morley P, Buehan of isehemic cerebral cell death.Prog CardiovaseDis,1999, 42(3):85-207.
[12]Mies QKohno K,Hossman KA,MK-801,a glutmate antagonist,lowers flow threshold for inhibition of protein synthesis after middle cerebral artery occlusion of rat.Neurosci Lett,1993,155(1):65-68.
[13]Rother J,de-Crespingny AJ,D Arceuil H et al.Stroke,1996,27:980
[14]Kohon K,Hoehn-Berlage M, Mies QRelationship between diffusion-weighted MR images,cewebral biood flow,and energy state in experimental brain infarction.Magn Reson Imaging,1995,13(1):73-80.
[15]Fatar M,Stroick M,Griebe M,.et al.Matrixmetallo proteinases in cerebrovascular diseases. Cerebrovasc Dis,2005,20:141-151.
[16]Cunningham LA,Wetzel M,Rosenberg GA.Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia,2005,50:329-339.
[17]Zoppo GJ,Milner R,Mabuchi T,et al.Microglial activation and matrix protease generation during focal cerebral ischemia.Stroke,2007,38:646-651.
[18]Lewen A,Mqtz P,Chan PH.Free radial Pathways in CNS injury.J neurotrauma.2000,17(10):871-890.
[19]Doyle KP, Simon RP, Stenztl-PeoreMP. Mechanisms of ischemic brain damage [J].Neuropharmacology,2008, do:i 10.1016/j neuropharm.2008.01.005
[20]Duan W,Gui L,Zhou Z,et al.Adenosine A(2A)receptor deficiencyexacerbates white matter lesions and cognitive deficits induced bychronic cerebral hypoperfusion in mice[J].Neurol Sci,2009,285(1):39-45.
[21]Stanimirovic D,Satoh K.Inflammatory mediations of cerebral endothelium:amole in ischemic brain inflammtion.Brain Pathol,2000,10(1):113-126.
[22]Vilan N,Castillo J,DavolosA,et al.Proinflamatory cytokines and early neurological worsening in ischemic stroke[J].Stroke,2000,31(10):2325-2329.
[23]Feuerstein GZ, Liu T, Barone FC. Cytokines,inflammation, and brain injury:role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev,1994,6(4):341-360.
[24]Ritter LS,Orozco JA,Coull BM,et al.Leukocyte accumulation and hemodynamic changes in the cerebral microcriculation during early reperfusion after stroke,2000,31(5):1153-1161.
[25]Del Zoppo GJ,Schmid-Schonbein GW,Mori E,et al.Polymorphonucl-ear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons.Stroke,1991,22:1276-1283.
[26]Kochanek P,Hallenbeck JM.Polymorphonuclear Leukocytes and Monmcytes/Macrophages in the Pathogenesis of Cerebral Ischemia and Stroke.Stroke,1992,23(9):1367-1375.
[27]滕厚军,赵瑛.慢性脑缺血神经胶质细胞损伤与血管性痴呆的研究进展[J].中国脑血管病杂志,2008,5(10)：473-476.
[28]Streit WJ,Walter SA,Pennell NA.Reactive microgliosis [J]. ProgNeurobiol,1999,57(6):563-581.
[29]Siesjo BK:Cell damagr in the brain:A speculative synthesis.J CerebBloodFlowMetab,1981; 1:155-85.
[30]Portera-Cailliau C,Price DL,Martin LJ,Excitotoxic neuronal death in the immature brain is an apoptosis-necrosis morphological continuum.J Comp Neurol,1997,378(1):70-87.
[31]Koh JY, Suh SW, Gwag BJ,et al. The role of zinc inselective neuronal death following transient global ischemia. Science,1996,272:1013-1016.
[32]Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol,1996,6:667-672.
[33]丁宏岩,董强.肝素体外诱导低密度脂蛋白—载脂蛋白a—纤维蛋白原沉淀系统在脑梗死中的临床应用[J].国外医学脑血管疾病分册,2002, (10)5：370-373.
[33]余巧燕,孙晋民.溶栓药物的研究进展[J].医学理论与实践,2009,22(1)：30-33
[34]Del Zoppo GJ,Saver JL,Jauch EC,et al;Amercian Heart Association Stroke Council.Expansion of the window for treatment of actue ischemic stroke with intravenous tissue plasminogen activator:a science advisory from the American heart Association.Stoke,2009,40:2945-2948
[35]朱丽君.急性脑梗死的药物治疗[J].急性脑梗死的药物治疗,2008,29(1)：48-51.
[36]刘庆新,张苏明.急性脑出血继发缺血半暗带的研究进展[J].国外医学：脑血管疾病分册,2002,10(3)：191-194.
[37]匡培根.神经系统疾病药物治疗学[M].北京：人民卫生出版社,2002：241-250
[38]冯留信.神经保护治疗的现状及进展[J].中国现代医生.2008,46,(6)：72-73
[39]章祥.脑卒中诊断治疗学[M].北京：人民军医出版社,2002：102-103
[40]Yuki S,Kogure K.The changes of LCGU and rCBF in the MCA Oclusion recirculation model in rats and the ameliorating efect of MCI-186,a novel free radical scavenger.Mol Chem Neuropathol,1997,32(1-3):123-128.
[41]Takahashi QSakurai M,Abe K,et al.MCI-186 prevents spinal cord damage and affects enzyme levels of nitric oxide synthase and Cu/Zn superoxide dismutase after transient ischemia in rabbits[J].J Thorac Cardiovasc Surg,2003,126(5):1461-1466.
[42]Gu Z,Kaul M,Yan B,et al.Snitrosylation of matrix metalloproteinases:signaling pathway to neuronal cell death. Science,2002,297 (5584):1186-1190.
[43]Higashi Y.Edaravone for the treatment of acute cerebral infarction:role ofendothelium derived nitric oxide and oxidative stress[J].Expert Opin Pharmacother,2009,10(2):323-331.
[44]Xiao B,Bi FF,Hu YQ,et al.Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats[J].Neurotox Res,2007,12(3):155-162.
[45]朱东铭,罗成宏.依达拉奉治疗高血压脑出血的临床疗效观察[J].国际医药卫生导报,2006,12(31)：88-89
[46]Visse R,Nagase H.Matrix metalloproteinases and tissue inhibitors of metalloproteinases:structure,function,and biochemistry. CircRes,2003,92(8):827-839.
[47]胡海涛,吴继敏,王爽,等.依达拉奉对大鼠局灶性脑缺血的保护作用[J].中国药学杂志, 2005,40(19)：1463.
[48]ToyodaK, FujiiK, KamouchiM, et a.l Free radical scavenger,edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci,2004,221:11-17.
[49]邓树荣.脑缺血亚低温脑保护研究的进展与临床应用[J].医学文选,2003,23(4)：557-559
[50]丁宏岩,董强.肝素体外诱导低密度脂蛋白—载脂蛋白a—纤维蛋白原沉淀系统在脑梗死中的临床应用[J].国外医学脑血管疾病分册,2002, (10)5：370-373.
[51]Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemicstroke. Cochrane Database Syst Rev,2004, (3):24.
[52]Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med,1995,333:1588-1593.
[53]The Publications Committee for the Trial of ORG10172in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid,ORG10172(danaparoid), and outcome after acute ischemic stroke:a randomized controlled trial. JAMA,1998,279:1265-1272.
[54]杨友松,高国勋血液稀释疗法及其临床应用系统评价[J].实用医院临床杂志,2008,3,(5)：26-28
[55]FRIEDRICH G, IUCA R, HEINRICHM, eta.l local intra-arterial thrombolysis in acute ischemic stroke[J]. Stroke,1998,29:1894-1900.
[56]TOSHIHIRO M D, SABURO M D, ICHIRO M D,et al.Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries[J]. Stroke,1998,29:2568-2574.
[57]国家中医药管理局脑病急症协作组.中风病诊断与疗效评定标准(试行)[J].北京中医药大学学报,1996,19(1)：55-56
[58]谭红刚,辨证治疗脑梗死120例[J].光明中医,2006,21(5)：67-68
[59]缪钟丽.中风证治十法[J].山东中医志,1995,2(14)：58-59
[60]蒋红玉.缺血性中风108例临床观察[J].中医杂志,1996(2)：96-97
[61]王建华,王永炎.出血性中风＆缺血性中风急性期证候演变规律的研究[J].中国中医急症,2001,10(4)：215-217
[62]沈思钰,傅晓东,钱善风.中医药对缺血性中风神经保护作用的机理探讨及评价[J].中国中医急症,2004,13(12)：838-839
[63]黄选华.辨证通腑治疗中风急性期96例疗效观察[J].广西中医学院学报,2001,18(1)：47
[64]屈营,董雪.中风辨证治疗恢复期中风106例[J].辽宁中医学院学报,2002,4(4)：300
[65]张树泉.调气法在急性脑梗死溶栓治疗中的应用[J].山东中医杂志,2005,24(5)：265-266
[66]裘昌林.中风病研究概况[J].浙江中西医结合杂志,2000,10(12)：705-707
[67]王妍,李成.清开灵治疗脑卒中急性期34例[J].天津中医,2000,17(3)：15—17
[68]刘方,白文.醒脑静注射液治疗急性脑血管病35例临床研究[J].中西医结合心脑血管病杂志,2004,2(9)：511-513
[69]于锋,金亦涛,綦春玉等.脉络宁注射液药理学研究进展[J].中国新药杂志,2002,11(12)：920-924
[70]肖勤选,金香兰,蒋红信等.脉络宁治疗急性期脑梗塞398例临床疗效观察[J].辽宁医学杂志,2001,15(2)：97-98.
[71]陆寿康.头针治疗中风偏瘫及其疗效的评估[J].中医杂志,1991,(10)：49.
[72]马松涛.头针治疗中风偏瘫的临床观察[J].河北中医,1993,15(1)：28.
[73]于致顺.头针刺激区与头部腧穴关系[J].中医药学报,1987,1(1)：7.
[74]石宪,张志芳,李晓燕,等.头部“菱形区”,治疗中风偏瘫的临床研究[J].针灸学报,1991,7(3)：35.
[75]许佳年,贾怡蓓,韩天雄,武雪宇,陈佳红,庄海春.针药结合对脑梗塞患者血脂和血液流变学的影响[J].辽宁中医杂志,2006,33(12)：1528-1529.
[76]李熳,穆腊梅.头针疗法治疗中风进展[J].中国针灸,1993,11(3)：87.
[77]沈特立,周冬梅,王兴.头针治疗急性脑梗塞70例临床研究[J].针灸临床杂志,2000,16(2)：31-33
[78]张丹莉.针刺阳明经榆穴对脑卒中患者运动功能的影响[J].中国临床康复.2005,9(13)：148.
[79]王友仁,徐止帆.针药综合治疗中风偏瘫144例[J].江苏中医.1995,(1)：39.
[80]石学敏.针刺治疗中风病的临床研究[J].上海针灸杂志,1992,(4)：4.
[81]申鹏飞,石学敏.针刺对急性期超早期脑梗死患者脑氧代谢的影响[J].光明中医,2009,24(2)：303-305.
[82]许能贵,马勤耘,许冠蒸等.电针对局灶性脑缺血大鼠脑血流量、脑含水量,SOD,MDA的影响[J].针刺研究,1998,23(3)：175.
[83]许能贵,马勤耘,侯思伟.电针对局灶性脑缺血大鼠兴奋性氨基酸含量的影响[J].中国针灸,1999,19(7)：431-432.
[84]许能贵,马勤耘,朱舜丽等.电针对局灶性脑缺血大鼠中枢单胺类神经递质的影响[J].中国中医基础医学杂志,1999,5(12)：56-57.
[85]郑谅,江钢辉,李艳慧.调和阴阳法治疗中风偏瘫的临床研究[J].针刺研究,1999,24(4)：249-250.
[86]常亮,侯本赤.针刺井穴治疗脑卒中下肢弛缓性瘫痪22例[J].辽宁中医学院学报,2006,(3)：102.
[87]殷克敬,杜元灏,王瑞辉.针刺治疗中风急性期机理研究[J].针灸临床杂志,1997,8：16-19..
[88]范刚启.针灸治疗中风病[M].上海：第一军医大学出版社,2001：120-123.
[89]雷龙鸣,吴林,胡跃强.不同针刺方案对脑梗死偏瘫患者康复及病灶侧大脑中动脉平均血流速度的影响[J].中国针灸,2009,29(7)：517-520.
[90]张晓霞,冯毅.火针治疗缺血性中风的临床观察[J].北京中医,2001,5,54-55.
[91]姜华,王满侠,郭健等.子午流注纳甲法治疗急性缺血性脑血管病及对IL-6水平的影响[J].甘肃中医学院学报,2003,20(1)：45-47.
[92]高先凤,川芎嗪穴位注射对脑梗死肢体功能恢复的疗效观察[J].中医药临床杂志,2008,20(6)：583-584.
[93]石奕丽刺络拔罐法治疗假性球麻痹46例临床观察[J].河北中医,1997,19(2)：43.
[94]郭义,周智良,周国平,等1中风初起的急救措施——手十二井穴刺络放血法的临床与实验研究[J].上海针灸杂志,1997,16(2)：11.
[95]韩宝杰,刺络疗法对中风病患者血液.变学影响的临床观察[J].天津中医,2001,18(1)：28-29.
[96]解庆凡,田胜利等.大全息针法治疗中风偏瘫230例临床观察[J].北京中医药大学学报,2005,23(3)：74
[97]曹岱,赵辉等.马丹阳天星十二穴担截法治疗缺血性中风临床研究[J].中国针灸,2002,22(9)：591
[98]徐斌,陆金平,孙建华等.针药结合对缺血性脑血管病患者血浆神经肽的影响[J].中国临床康复,19(7)：2646-2647
[99]许佳年,贾怡蓓,韩天雄等.针药结合对脑梗塞患者血脂和血液流变学的影响[J].辽宁中医杂志,2006,33(12)：1528-1529.
[100]陈莉秋.针药结合治疗脑梗死32例疗效观察[J].河北中医,2008,30(1)：67-68.
[101]李宗桥,韩永,陈会君.针药结合对急性脑梗死患者神经功能恢复的影响[J].针灸临床杂志,2006,22(10)：25-26.
[102]高建平,邱霞,廉世松.早期补肾醒脑针法干预缺血性中风患者神经功能缺损的临床观察[J].中华中医药杂志,2008,23(4)：367-368.
[103]金智秀,图娅,洪银珠等.头针、体针和针药结合治疗对全脑缺血大鼠钙调素活性即 刻影响的比较研究[J].针刺研究,2004,29(14)：18-19
[104]马惠芳,郭长青,邬继红等.针刺“水沟”穴与针药结合对实验性全脑缺血大鼠脑组织钙调素活性影响的实验研究[J].北京中医药大学学报,2003,26(1)：84-85
[105]陶陶,徐坚,董佑忠等.电针及天麻对大鼠脑缺血再灌注后神经细胞凋亡及相关蛋白Bcl-2、 Bax表达的影响[J].中国针灸,2004,24(9)：645-648
[106]成泽东,陈以国,王树东.针药结合对脑缺血再灌注大鼠血清SOD、 MDA及海马组织超微结构的影响[J].中医研究,2008,21(10)：9-11
[107]严文广,谢雪姣,黄政德等.针药结合干预大鼠局灶性脑缺血组织ATP酶活性及能量代谢的研究[J].湖南中医药大学学报,2007,27(3)：59-62
[108]全国第四界脑血管疾病会议.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29,(6)：381.
[109]中华医学会全国第四次脑血管病学术会议.脑卒中患者神经功能缺损程度评分标准[S].中华神经科杂志,1996,29(6)：381-383
[110]杨志新,石学敏,醒脑开窍针刺法治疗中风疗效与安全性的系统评价[J].中国针灸,2007,27(8)：601-607.
[111]王茂斌.脑卒中偏瘫患者肢体运动功能的头针评测方法[J].中国头针医学杂志,1992,7(2)：81.
[112]Keith RA, Granger CV, Hamilton BB, et al. The functional independence measure:a new tool for rehabilitation.In:Eisenberg M, Grzesia R.eds. Advances in clinical rehabilitation [M]. NewYork:SpringeVerlag,1987:6-18.
[113]Holbrook M, Skilbeck CF. An activities index for use with stroke patients [J]. Age Ageing,1983,12:166-170
[114]周维金,孙启良.瘫痪康复评定手册[M].北京：人民卫生出版社,2006：12-20.
[115]王志义.中药、针刺、针药并举对脑卒中偏瘫康复的疗效对比分析[J].现代康复,2001,5(6)：130
[116]高希言等.针药结合研究的探讨[J].中医杂志,1999,40(9)：562-563